New drug combo aims to shrink dangerous heart plaque
NCT ID NCT06372925
Summary
This study is testing if adding a cholesterol-lowering injection called Inclisiran to standard statin pills can better reduce the fatty buildup (plaque) in heart arteries of people who recently had a heart attack. About 318 participants in China will receive either the drug combination or just the statin pill for one year. Doctors will use special imaging inside the arteries to measure if the plaque shrinks or becomes more stable.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE, ATHEROSCLEROTIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Hefei, Anhui, 230001, China
-
Novartis Investigative Site
Fuzhou, Fujian, 350001, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510030, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510080, China
-
Novartis Investigative Site
Shenzhen, Guangdong, 518000, China
-
Novartis Investigative Site
Zunyi, Guizhou, 563000, China
-
Novartis Investigative Site
Harbin, Heilongjiang, 150086, China
-
Novartis Investigative Site
Zhengzhou, Henan, 450003, China
-
Novartis Investigative Site
Wuhan, Hubei, 430060, China
-
Novartis Investigative Site
Nanchang, Jiangxi, 330006, China
-
Novartis Investigative Site
Changchun, Jilin, 130033, China
-
Novartis Investigative Site
Dalian, Liaoning, 116023, China
-
Novartis Investigative Site
Jining, Shandong, 272000, China
-
Novartis Investigative Site
Xian, Shanxi, 710061, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610072, China
-
Novartis Investigative Site
Wenzhou, Zhejiang, 325027, China
-
Novartis Investigative Site
Beijing, 101149, China
-
Novartis Investigative Site
Lanzhou, 730000, China
-
Novartis Investigative Site
Tianjin, 300000, China
Conditions
Explore the condition pages connected to this study.